Phase
Condition
Mood Disorders
Dementia
Mild Cognitive Impairment
Treatment
Placebo
ALTO-101
Placebo Transdermal Delivery System
Clinical Study ID
Ages 21-55 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Schizophrenia diagnosis for at least one year
Cognitive impairment
Stable doses of 1-2 antipsychotic medication(s) for at least 8 weeks at Visit 2
Positive and Negative Syndrome Scale (PANSS) score: items P1, P3-P6 ≤ 5 and item P2and P7 ≤ 4 during screening
Have a body mass index (BMI) ≥ 18.0 and ≤ 37.0 kg/m2 (inclusive)
Willing to comply with all study assessments and procedures
Exclusion
Exclusion Criteria:
Evidence of unstable medical condition
Acute psychiatric decompensation or severity of symptoms requiring psychiatrichospitalization in past 6 months
Diagnosis of schizoaffective or bipolar affective disorder, dementia, orintellectual disability
Current episode of major depressive disorder (MDD)
Use of mood stabilizer, clozapine, and/or daily benzodiazepine
Current moderate or severe substance use disorder
Study Design
Connect with a study center
Site 5038
Garden Grove, California 92845
United StatesActive - Recruiting
Site 5083
Garden Grove, California 92845
United StatesActive - Recruiting
Site 5063
Los Angeles, California 90015
United StatesSite Not Available
Site 5060
Hollywood, Florida 33024
United StatesSite Not Available
Site 5056
Chicago, Illinois 60640
United StatesActive - Recruiting
Site 5062
Gaithersburg, Maryland 20877
United StatesActive - Recruiting
Site 5055
Cedarhurst, New York 11516
United StatesSite Not Available
Site 5077
New York, New York 10032
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.